Ledipasvir

Item number	Size	Delivery time	Price
TGM-T6200-1mg	1 mg	7 - 10 business days*	33.00€
TGM-T6200-2mg	2 mg	7 - 10 business days*	45.00€
TGM-T6200-5mg	5 mg	7 - 10 business days*	72.00€
TGM-T6200-1mL	1 ml	7 - 10 business days*	89.00€
TGM-T6200-10mg	10 mg	7 - 10 business days*	89.00€
TGM-T6200-25mg	25 mg	7 - 10 business days*	161.00€
TGM-T6200-50mg	50 mg	7 - 10 business days*	269.00€
TGM-T6200-100mg	100 mg	7 - 10 business days*	466.00€
TGM-T6200-500mg	500 mg	7 - 10 business days*	1,070.00€

If you have any questions, please use our Contact Form.
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk

Description: Ledipasvir (GS-5885) is a Hepatitis C Virus NS5A Inhibitor. The mechanism of action... more

Close menu

Product information "Ledipasvir"

Description: Ledipasvir (GS-5885) is a Hepatitis C Virus NS5A Inhibitor. The mechanism of action of ledipasvir is as a P-Glycoprotein Inhibitor, and Breast Cancer Resistance Protein Inhibitor. Target: SARS-CoV, HCV Protease. Smiles: COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1c1ncc([nH]1)-c1ccc2-c3ccc(cc3C(F)(F)c2c1)-c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)C. References: Link JO, et al. Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem. 2014 Mar 13,57(5):2033-46.

Keywords:	GS-5885
Supplier:	TargetMol
Supplier-Nr:	T6200

Properties

Application:	Targets Hepatitis C virus non-structural protein 5A (NS5A)
MW:	889 D
Formula:	C49H54F2N8O6
Format:	32160405

Database Information

CAS :	1256388-51-8\| Matching products
KEGG ID :	K22275 \| Matching products

Handling & Safety

Storage:	-20°C
Shipping:	+4°C (International: +4°C)

Caution
Our products are for laboratory research use only: Not for administration to humans!

Information about the product reference will follow. more

Close menu

You will get a certificate here

Go back

Read, write and discuss reviews... more

Close menu

Customer review for "Ledipasvir"

Write a review